MTOR inhibitor-based combination therapies for pancreatic cancer

BACKGROUND: Although the mechanistic target of rapamycin (MTOR) kinase, included in the mTORC1 and mTORC2 signalling hubs, has been demonstrated to be active in a significant fraction of patients with pancreatic ductal adenocarcinoma (PDAC), the value of the kinase as a therapeutic target needs furt...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Hassan, Zonera, Schneeweis, Christian, Wirth, Matthias, Veltkamp, Christian, Dantes, Zahra, Feuerecker, Benedikt, Ceyhan, Güralp O, Knauer, Shirley K, Weichert, Wilko, Schmid, Roland M, Stauber, Roland, Arlt, Alexander, Krämer, Oliver H, Rad, Roland, Reichert, Maximilian, Saur, Dieter, Schneider, Günter
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2018
Assuntos:
Translational Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5808033/
https://ncbi.nlm.nih.gov/pubmed/29384525
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2017.421
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados